These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36853683)

  • 21. Evaluation of Parameters Impacting Drug Susceptibility in Intracellular Trypanosoma cruzi Assay Protocols.
    Yang G; Lee N; Ioset JR; No JH
    SLAS Discov; 2017 Feb; 22(2):125-134. PubMed ID: 27729503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Designing and exploring active N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against three Trypanosoma cruzi strains more prevalent in Chagas disease patients.
    Palace-Berl F; Pasqualoto KF; Jorge SD; Zingales B; Zorzi RR; Silva MN; Ferreira AK; de Azevedo RA; Teixeira SF; Tavares LC
    Eur J Med Chem; 2015; 96():330-9. PubMed ID: 25899337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An in vitro iron superoxide dismutase inhibitor decreases the parasitemia levels of Trypanosoma cruzi in BALB/c mouse model during acute phase.
    Olmo F; Urbanová K; Rosales MJ; Martín-Escolano R; Sánchez-Moreno M; Marín C
    Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):110-6. PubMed ID: 26236582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
    Engel JC; Ang KK; Chen S; Arkin MR; McKerrow JH; Doyle PS
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3326-34. PubMed ID: 20547819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.
    Morillo CA; Waskin H; Sosa-Estani S; Del Carmen Bangher M; Cuneo C; Milesi R; Mallagray M; Apt W; Beloscar J; Gascon J; Molina I; Echeverria LE; Colombo H; Perez-Molina JA; Wyss F; Meeks B; Bonilla LR; Gao P; Wei B; McCarthy M; Yusuf S;
    J Am Coll Cardiol; 2017 Feb; 69(8):939-947. PubMed ID: 28231946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination With Tomatidine Improves the Potency of Posaconazole Against
    Rocha-Hasler M; de Oliveira GM; da Gama AN; Fiuza LFA; Fesser AF; Cal M; Rocchetti R; Peres RB; Guan XL; Kaiser M; Soeiro MNC; Mäser P
    Front Cell Infect Microbiol; 2021; 11():617917. PubMed ID: 33747979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pentamidine antagonizes the benznidazole's effect in vitro, and lacks of synergy in vivo: Implications about the polyamine transport as an anti-Trypanosoma cruzi target.
    Seguel V; Castro L; Reigada C; Cortes L; Díaz MV; Miranda MR; Pereira CA; Lapier M; Campos-Estrada C; Morello A; Kemmerling U; Maya JD; López-Muñoz R
    Exp Parasitol; 2016 Dec; 171():23-32. PubMed ID: 27729250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
    Ferreira de Almeida Fiuza L; Peres RB; Simões-Silva MR; da Silva PB; Batista DDGJ; da Silva CF; Nefertiti Silva da Gama A; Krishna Reddy TR; Soeiro MNC
    Eur J Med Chem; 2018 Apr; 149():257-268. PubMed ID: 29501946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo antiparasitic activity of Physalis angulata L. concentrated ethanolic extract against Trypanosoma cruzi.
    Meira CS; Guimarães ET; Dos Santos JA; Moreira DR; Nogueira RC; Tomassini TC; Ribeiro IM; de Souza CV; Ribeiro Dos Santos R; Soares MB
    Phytomedicine; 2015 Oct; 22(11):969-74. PubMed ID: 26407938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A flow cytometer-based method to simultaneously assess activity and selectivity of compounds against the intracellular forms of Trypanosoma cruzi.
    Miranda CG; Solana ME; Curto MLA; Lammel EM; Schijman AG; Alba Soto CD
    Acta Trop; 2015 Dec; 152():8-16. PubMed ID: 26272680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New Imidazole-Based Compounds Active Against Trypanosoma cruzi.
    Adeyemi OS; Molina MT; Eseola AO; Fonseca-Berzal C; Gómez-Barrio A
    Comb Chem High Throughput Screen; 2017; 20(1):20-24. PubMed ID: 28071587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High throughput screening for anti-Trypanosoma cruzi drug discovery.
    Alonso-Padilla J; Rodríguez A
    PLoS Negl Trop Dis; 2014 Dec; 8(12):e3259. PubMed ID: 25474364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural Optimization and Biological Activity of Pyrazole Derivatives: Virtual Computational Analysis, Recovery Assay and 3D Culture Model as Potential Predictive Tools of Effectiveness against
    Orlando LMR; Lechuga GC; da Silva Lara L; Ferreira BS; Pereira CN; Silva RC; Dos Santos MS; Pereira MCS
    Molecules; 2021 Nov; 26(21):. PubMed ID: 34771151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study.
    Perez-Mazliah DE; Alvarez MG; Cooley G; Lococo BE; Bertocchi G; Petti M; Albareda MC; Armenti AH; Tarleton RL; Laucella SA; Viotti R
    J Antimicrob Chemother; 2013 Feb; 68(2):424-37. PubMed ID: 23104493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.
    Molina I; Gómez i Prat J; Salvador F; Treviño B; Sulleiro E; Serre N; Pou D; Roure S; Cabezos J; Valerio L; Blanco-Grau A; Sánchez-Montalvá A; Vidal X; Pahissa A
    N Engl J Med; 2014 May; 370(20):1899-908. PubMed ID: 24827034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
    Vallejo M; Reyes PP; Martinez Garcia M; Gonzalez Garay AG
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004102. PubMed ID: 33305846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful Aspects of the Coadministration of Sterol 14α-Demethylase Inhibitor VFV and Benznidazole in Experimental Mouse Models of Chagas Disease Caused by the Drug-Resistant Strain of Trypanosoma cruzi.
    Guedes-da-Silva FH; Batista DDGJ; Da Silva CF; Pavão BP; Batista MM; Moreira OC; Souza LRQ; Britto C; Rachakonda G; Villalta F; Lepesheva GI; Soeiro MNC
    ACS Infect Dis; 2019 Mar; 5(3):365-371. PubMed ID: 30625275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo activity of voriconazole and benznidazole combination on trypanosoma cruzi infection models.
    Gulin JEN; Eagleson MA; López-Muñoz RA; Solana ME; Altcheh J; García-Bournissen F
    Acta Trop; 2020 Nov; 211():105606. PubMed ID: 32598923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of Benznidazole in Experimental Chronic Chagas Disease Using the Swiss Mouse-Berenice-78 Trypanosoma cruzi Strain Model.
    de Jesus SM; Pinto L; Moreira FL; Nardotto GHB; Cristofoletti R; Perin L; Fonseca KDS; Barbêdo P; Bandeira LC; Vieira PMA; Carneiro CM
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Miltefosine and Benznidazole Combination Improve Anti-
    Gulin JEN; Bisio MMC; Rocco D; Altcheh J; Solana ME; García-Bournissen F
    Front Cell Infect Microbiol; 2022; 12():855119. PubMed ID: 35865815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.